Younossi Z - Search Results

1

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Among authors: younossi z. Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24. Ann Hepatol. 2024. PMID: 37364816 Free article. Review.

2

Treatment of Crigler-Najjar type II with small-dose phenobarbital.

Younossi ZM, Foroozan P. Younossi ZM, et al. Dig Dis Sci. 1995 Mar;40(3):575. doi: 10.1007/BF02064372. Dig Dis Sci. 1995. PMID: 7895547 No abstract available.

3

Non-alcoholic fatty liver disease: an overview.

Mulhall BP, Ong JP, Younossi ZM. Mulhall BP, et al. J Gastroenterol Hepatol. 2002 Nov;17(11):1136-43. doi: 10.1046/j.1440-1746.2002.02881.x. J Gastroenterol Hepatol. 2002. PMID: 12453271 Review.

4

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Poynard T, et al. Among authors: younossi z. Hepatology. 2003 Jul;38(1):75-85. doi: 10.1053/jhep.2003.50267. Hepatology. 2003. PMID: 12829989 Clinical Trial.

5

Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment.

Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Spiegel BM, et al. Hepatology. 2005 Apr;41(4):790-800. doi: 10.1002/hep.20659. Hepatology. 2005. PMID: 15791608 Review.

6

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. Younossi ZM, et al. Hepatology. 2005 Sep;42(3):665-74. doi: 10.1002/hep.20838. Hepatology. 2005. PMID: 16116632

7

Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

Ong JP, Pitts A, Younossi ZM. Ong JP, et al. J Hepatol. 2008 Oct;49(4):608-12. doi: 10.1016/j.jhep.2008.06.018. Epub 2008 Jul 9. J Hepatol. 2008. PMID: 18682312

8

Long-term follow-up of patients with nonalcoholic fatty liver.

Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Rafiq N, et al. Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8. doi: 10.1016/j.cgh.2008.11.005. Epub 2008 Nov 7. Clin Gastroenterol Hepatol. 2009. PMID: 19049831

9

Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.

Rafiq N, Younossi ZM. Rafiq N, et al. Expert Rev Gastroenterol Hepatol. 2008 Apr;2(2):207-15. doi: 10.1586/17474124.2.2.207. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072356 Review.

10

Treatment regimens for non-alcoholic fatty liver disease.

Lam BP, Younossi ZM. Lam BP, et al. Ann Hepatol. 2009;8 Suppl 1:S51-9. Ann Hepatol. 2009. PMID: 19381125 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

733 results

Search Page